1. Agoti CN, Otieno JR, Gitahi CW, Cane PA, Nokes DJ (2014) Rapid spread and diversification of respiratory syncytial virus genotype ON1, Kenya. Emerg Infect Dis 20(6):950–959
2. Aherne W, Bird T, Court SD, Gardner PS, McQuillin J (1970) Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 23(1):7–18
3. Alnylam Pharmaceuticals Inc. (2005) Alnylam initiates phase i clinical study of ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. [cited 2017 November 15]. Available from:
http://investors.alnylam.com/news-releases/news-release-details/alnylam-initiates-phase-i-clinical-study-aln-rsv01-rnai
4. Ark Biosciences Inc. (2015) Ark biosciences’ anti-RSV AK0529 successfully completes phase I study. [cited 2017 November 17]. Available from:
http://www.arkbiosciences.com/index.php?g=&m=article&a=index&id=17&cid=12
5. Battles MB, Langedijk JP, Furmanova-Hollenstein P, Chaiwatpongsakorn S, Costello HM, Kwanten L, Vranckx L, Vink P, Jaensch S, Jonckers THM, Koul A, Arnoult E, Peeples ME, Roymans D, McLellan JS (2016) Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol 12(2):87–93